Close
Almac
Achema middle east

In Britain, The ABPI Sets Out A Clear Antimicrobial Goal

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

The Association of the British Pharmaceutical Industry (ABPI) has reemphasized its message to the industry about the development of new antibiotics on the eve of World Antibiotic Awareness Week.

Antibiotic-resistant illnesses are thought to have caused 1.2 million deaths worldwide in 2019, while in England, over 90,000 people were admitted to hospitals in 2019–20. But the world’s supply of new antibiotics hasn’t been able to stop the problem from getting worse.

Additionally, a significant global challenge to contemporary medicine is being created by the development of drug-resistant microorganisms more quickly than new antimicrobial therapies.

The goal of World Antibiotic Awareness Week this year is to increase awareness and understanding of antimicrobial resistance (AMR). Better behaviour among the general public, healthcare professionals, and policymakers will be promoted by the event in an effort to stop the antibiotic resistance from spreading. The core pillars of contemporary medicine are under threat from antibiotic resistance, according to Amit Aggarwal, executive director of medical affairs at the ABPI. The use and administration of these essential medications by individual healthcare professionals and patients will make a significant contribution to the worldwide effort needed to overcome the dilemma.

The UK is already playing a pioneering role in combating resistance to antibiotics through reforms to how it rewards and incentivizes antibiotic research, but it will not win this battle by itself, he continued. The advancement of new antimicrobial therapies must be given top priority while they continue to encourage global efforts to enhance the way they employ currently available antibiotics.

Antibiotic resistance happens when the bacteria that causes an infection cannot be treated with the antimicrobial medications that are currently accessible.

 Every healthcare system in the world depends on the usage of antibiotics for routine medical procedures like tooth extractions, chemotherapy, sepsis, and surgery.

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »